Loading
The American head-to-head of the same two antibodies, in 1,137 patients, found no difference: 30.0 against 29.0 months. Read next to FIRE-3, it is why sidedness had to be invoked.
Venook, Niedzwiecki, Lenz and colleagues enrolled previously untreated patients aged 18 or older with advanced or metastatic KRAS wild-type colorectal cancer at community and academic centres across the National Clinical Trials Network in the United States and Canada between November 2005 and March 2012. Patients chose mFOLFOX6 or FOLFIRI as their chemotherapy and were randomised to cetuximab (578) or bevacizumab (559). The primary endpoint was overall survival; last follow-up was December 2015.
Of 1,137 patients (median age 59; 440, 39 percent, women), 1,074 (94 percent) met eligibility criteria, and 82 percent had experienced disease progression by the data cut.
The negative counterweight to FIRE-3. The two trials are reconciled only by primary tumour side, which is why the sidedness analysis rather than either trial is what guidelines now cite.
The analysis that put 'left-sided, RAS and BRAF wild-type' into every guideline as the anti-EGFR population, and made an anatomical fact into a treatment-selection biomarker.
Together with PARADIGM it makes the EGFR antibody the preferred first partner for chemotherapy in left-sided RAS wild-type disease; the survival gain without a progression-free survival gain remains one of the field's unexplained results.
Shares Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials, Sidedness (left vs right colon), Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, FOLFOX (5-FU, leucovorin, oxaliplatin) and the tag colorectal-evidence.
Shares FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3), FOLFIRI (5-FU, leucovorin, irinotecan), VEGF / VEGFR, Anti-angiogenic therapy and the tag colorectal-evidence.
Shares Sidedness (left vs right colon), FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation and the tag colorectal-evidence.
Shares Heinz-Josef Lenz, VEGF / VEGFR, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Anti-angiogenic therapy and the tag colorectal-evidence.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, EGFR and the tag colorectal-evidence.
Shares VEGF / VEGFR, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Anti-angiogenic therapy, Bevacizumab and the tag colorectal-evidence.
Shares Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, EGFR, KRAS, Monoclonal antibodies and the tag colorectal-evidence.
Shares VEGF / VEGFR, Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation, Anti-angiogenic therapy, Colorectal cancer and the tag colorectal-evidence.